nach oben

Arthritis Research & Therapy

Erschienen in:

01.03.2003 | Review

Aggrecanases and cartilage matrix degradation

verfasst von: Hideaki Nagase, Masahide Kashiwagi

Erschienen in: Arthritis Research & Therapy | Ausgabe 2/2003

Einloggen, um Zugang zu erhalten

Abstract

The loss of extracellular matrix macromolecules from the cartilage results in serious impairment of joint function. Metalloproteinases called 'aggrecanases' that cleave the Glu³⁷³–Ala³⁷⁴ bond of the aggrecan core protein play a key role in the early stages of cartilage destruction in rheumatoid arthritis and in osteoarthritis. Three members of the ADAMTS family of proteinases, ADAMTS-1, ADAMTS-4 and ADAMTS-5, have been identified as aggrecanases. Matrix metalloproteinases, which are also found in arthritic joints, cleave aggrecans, but at a distinct site from the aggrecanases (i.e. Asn³⁴¹–Phe³⁴²). The present review discuss the enzymatic properties of the three known aggrecanases, the regulation of their activities, and their role in cartilage matrix breakdown during the development of arthritis in relation to the action of matrix metalloproteinases.

Hinegård D, Lorenzo P, Sanxe T: Matrix glycoprotein, proteoglycans, and cartilage. In Kelly's Textbook of Rheumatology. Edited by: Ruddy S, Harris ED Jr, Sledge CB. 2001, Philadelphia: WB Saunders Company, 41-53.

Evans CH, Brown TD: Role of physical and medical aspects in degradating the matrix. In Joint Cartilage Degradation: Basic and Clinical Aspects. Edited by: Woessner JF Jr, Howell DS. 1993, New York: Marcel Dekker, 187-208.

Burkhardt H, Schwingel M, Menninger H, Macartney HW, Tschesche H: Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. Arthritis Rheum. 1986, 29: 379-387.PubMed

Okada Y: Proteinase and matrix degradation. In Kelly's Textbook of Rheumatology. Edited by: Ruddy S, Harris ED Jr, Sledge CB. 2001, Philadelphia: WB Saunders Company, 55-72.

Tetlow LC, Adlam DJ, Woolley DE: Matrix metalloproteinase and proinflammatory cytokine production by chondrocytes of human osteoarthritic cartilage: associations with degenerative changes. Arthritis Rheum. 2001, 44: 585-594. 10.1002/1529-0131(200103)44:3<585::AID-ANR107>3.3.CO;2-3.PubMed

Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS, Woessner JF: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest. 1989, 84: 678-685.PubMedCentralPubMed

Caterson B, Flannery CR, Hughes CE, Little CB: Mechanisms involved in cartilage proteoglycan catabolism. Matrix Biol. 2000, 19: 333-344. 10.1016/S0945-053X(00)00078-0.PubMed

Mort JS, Billington CJ: Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res. 2001, 3: 337-341. 10.1186/ar325.PubMedCentralPubMed

Nagase H: Aggrecanase in cartilage matrix breakdown. Connective Tissue. 2001, 33: 27-32.

10.

Arner EC: Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol. 2002, 2: 322-329. 10.1016/S1471-4892(02)00148-0.PubMed

11.

Roughley PJ, Mort JS: Catabolism of proteoglycans. In Proteoglygans. Structure, Biology, and Molecular Interactions. Edited by: Iozzo RV. 2000, New York: Marcel Dekker, 93-113.

12.

Fosang AJ, Neame PJ, Hardingham TE, Murphy G, Hamilton JA: Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem. 1991, 266: 15579-15582.PubMed

13.

Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA: The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992, 267: 19470-19474.PubMed

14.

Flannery CR, Lark MW, Sandy JD: Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem. 1992, 267: 1008-1014.PubMed

15.

Sandy JD, Neame PJ, Boynton RE, Flannery CR: Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem. 1991, 266: 8683-8685.PubMed

16.

Ilic MZ, Handley CJ, Robinson HC, Mok MT: Mechanism of catabolism of aggrecan by articular cartilage. Arch Biochem Biophys. 1992, 294: 115-122. 10.1016/0003-9861(92)90144-L.PubMed

17.

Loulakis P, Shrikhande A, Davis G, Maniglia CA: N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J. 1992, 284: 589-593.PubMedCentralPubMed

18.

Sandy JD, Flannery CR, Neame PJ, Lohmander LS: The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373–Ala 374 bond of the interglobular domain. J Clin Invest. 1992, 89: 1512-1516.PubMedCentralPubMed

19.

Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum. 1993, 36: 1214-1222.PubMed

20.

Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, Rosenfeld SA, Copeland RA, Decicco CP, Wynn R, Rockwell A, Yang F, Duke JL, Solomon K, George H, Bruckner R, Nagase H, Itoh Y, Ellis DM, Ross H, Wiswall BH, Murphy K, Hillman MC, Hollis GF, Arner EC: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science. 1999, 284: 1664-1666. 10.1126/science.284.5420.1664.PubMed

21.

Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, Ellis DM, Tortorella MD, Pratta MA, Hollis JM, Wynn R, Duke JL, George HJ, Hillman MC, Murphy K, Wiswall BH, Copeland RA, Decicco CP, Bruckner R, Nagase H, Itoh Y, Newton RC, Magolda RL, Trzaskos JM, Burn TC: Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem. 1999, 274: 23443-23450. 10.1074/jbc.274.33.23443.PubMed

22.

Tang BL: ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol. 2001, 33: 33-44. 10.1016/S1357-2725(00)00061-3.PubMed

23.

Cal S, Obaya AJ, Llamazares M, Garabaya C, Quesada V, Lóez-Otín C: Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains. Gene. 2002, 283: 49-62. 10.1016/S0378-1119(01)00861-7.PubMed

24.

Kuno K, Okada Y, Kawashima H, Nakamura H, Miyasaka M, Ohno H, Matsushima K: ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett. 2000, 478: 241-245. 10.1016/S0014-5793(00)01854-8.PubMed

25.

Rodríguez-Manzaneque JC, Westling J, Thai SN, Luque A, Knäuper V, Murphy G, Sandy JD, Iruela-Arispe ML: ADAMTS1 cleaves aggrecan at multiple sites and is differentially inhibited by metalloproteinase inhibitors. Biochem Biophys Res Commun. 2002, 293: 501-508. 10.1016/S0006-291X(02)00254-1.PubMed

26.

Flannery CR, Little CB, Hughes CE, Caterson B: Expression of ADAMTS homologues in articular cartilage. Biochem Biophys Res Commun. 1999, 260: 318-322. 10.1006/bbrc.1999.0909.PubMed

27.

Rawling ND, O'Brien EA, Barrett AJ: MEROPS: the protease database. Nucleic Acids Res. 2002, 70: 343-346. 10.1093/nar/30.1.343.

28.

[http://www.gene.ucl.ac.uk/nomenclature/genefamily/metallo.html]

29.

[http://www.gene.ucl.ac.uk/nomenclature/genefamily/adamts.html]

30.

Blobel CP, Wolfsberg TG, Turck CW, Myles DG, Primakoff P, White JM: A potential fusion peptide and an integrin ligand domain in a protein active in sperm-egg fusion. Nature. 1992, 356: 248-252. 10.1038/356248a0.PubMed

31.

Yagami-Hiromasa T, Sato T, Kurisaki T, Kamijo K, Nabeshima Y, Fujisawa-Sehara A: A metalloprotease-disintegrin participating in myoblast fusion. Nature. 1995, 377: 652-656. 10.1038/377652a0.PubMed

32.

Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T, Ohmoto H, Node K, Yoshino K, Ishiguro H, Asanuma H, Sanada S, Matsumura Y, Takeda H, Beppu S, Tada M, Hori M, Higashiyama S: Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002, 8: 35-40. 10.1038/nm0102-35.PubMed

33.

Pan D, Rubin GM: Kuzbanian controls proteolytic processing of Notch and mediates lateral inhibition during Drosophila and vertebrate neurogenesis. Cell. 1997, 90: 271-280. 10.1016/S0092-8674(00)80335-9.PubMed

34.

Qi H, Rand MD, Wu X, Sestan N, Wang W, Rakic P, Xu T, Artavanis-Tsakonas S: Processing of the notch ligand delta by the metalloprotease Kuzbanian. Science. 1999, 283: 91-94. 10.1126/science.283.5398.91.PubMed

35.

Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP: A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature. 1997, 385: 729-733. 10.1038/385729a0.PubMed

36.

Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Warner J, Willard D, Becherer JD: Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature. 1997, 385: 733-736. 10.1038/385733a0.PubMed

37.

Nardi JB, Martos R, Walden KK, Lampe DJ, Robertson HM: Expression of lacunin, a large multidomain extracellular matrix protein, accompanies morphogenesis of epithelial monolayers in Manduca sexta. Insect Biochem Mol Biol. 1999, 29: 883-897. 10.1016/S0965-1748(99)00064-8.PubMed

38.

Bork P, Beckmann G: The CUB domain. A widespread module in developmentally regulated proteins. J Mol Biol. 1993, 231: 539-545. 10.1006/jmbi.1993.1305.PubMed

39.

Colige A, Beschin A, Samyn B, Goebels Y, van Beeumen J, Nusgens BV, Lapière CM: Characterization and partial amino acid sequencing of a 107-kDa procollagen I N-proteinase purified by affinity chromatography on immobilized type XIV collagen. J Biol Chem. 1995, 270: 16724-16730. 10.1074/jbc.270.28.16724.PubMed

40.

Fernandes RJ, Hirohata S, Engle JM, Colige A, Cohn DH, Eyre DR, Apte SS: Procollagen II amino propeptide processing by ADAMTS-3. Insights on dermatosparaxis. J Biol Chem. 2001, 276: 31502-31509. 10.1074/jbc.M103466200.PubMed

41.

Colige A, Vandenberghe I, Thiry M, Lambert CA, van Beeumen J, Li SW, Prockop DJ, Lapière CM, Nusgens BV: Cloning and characterization of ADAMTS-14, a novel ADAMTS displaying high homology with ADAMTS-2 and ADAMTS-3. J Biol Chem. 2002, 277: 5756-5766. 10.1074/jbc.M105601200.PubMed

42.

Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD, Ginsburg D, Tsai HM: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001, 413: 488-494. 10.1038/35097008.PubMed

43.

Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B: von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998, 339: 1578-1584. 10.1056/NEJM199811263392202.PubMed

44.

Tsai HM, Lian EC: Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998, 339: 1585-1594. 10.1056/NEJM199811263392203.PubMedCentralPubMed

45.

Vazquez F, Hastings G, Ortega MA, Lane TF, Oikemus S, Lombardo M, Iruela-Arispe ML: METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem. 1999, 274: 23349-23357. 10.1074/jbc.274.33.23349.PubMed

46.

Tortorella MD, Pratta M, Liu RQ, Austin J, Ross OH, Abbaszade I, Burn T, Arner E: Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem. 2000, 275: 18566-18573. 10.1074/jbc.M909383199.PubMed

47.

Tortorella MD, Liu RQ, Burn T, Newton RC, Arner E: Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol. 2002, 21: 499-511. 10.1016/S0945-053X(02)00069-0.PubMed

48.

Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, Clark M, Liu C, Maki RA, Burnett D, Buttle DJ: Expression and activity of ADAMTS-5 in synovium. Eur J Biochem. 2001, 268: 1259-1268. 10.1046/j.1432-1327.2001.01990.x.PubMed

49.

Westling J, Fosang AJ, Last K, Thompson VP, Tomkinson KN, Hebert T, McDonagh T, Collins-Racie LA, LaVallie ER, Morris EA, Sandy JD: ADAMTS4 cleaves at the aggrecanase site (Glu373–Ala374) and secondarily at the matrix metalloproteinase site (Asn341–Phe342) in the aggrecan interglobular domain. J Biol Chem. 2002, 277: 16059-16066. 10.1074/jbc.M108607200.PubMed

50.

Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, Clowes AW: Versican V1 proteolysis in human aorta in vivo occurs at the Glu441–Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem. 2001, 276: 13372-13378. 10.1074/jbc.M009737200.PubMed

51.

Kuno K, Terashima Y, Matsushima K: ADAMTS-1 is an active metalloproteinase associated with the extracellular matrix. J Biol Chem. 1999, 274: 18821-18826. 10.1074/jbc.274.26.18821.PubMed

52.

Matthews RT, Gary SC, Zerillo C, Pratta M, Solomon K, Arner EC, Hockfield S: Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem. 2000, 275: 22695-22703. 10.1074/jbc.M909764199.PubMed

53.

Barret AJ: α₂-Macroglobulin. Methods Enzymol. 1981, 80: 737-754.

54.

Tortorella M, Pratta M, Liu RQ, Abbaszade I, Ross H, Burn T, Arner E: The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J Biol Chem. 2000, 275: 25791-25797. 10.1074/jbc.M001065200.PubMed

55.

Pratta MA, Tortorella MD, Arner EC: Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase. J Biol Chem. 2000, 275: 39096-39102. 10.1074/jbc.M006201200.PubMed

56.

Hörber C, Buttner FH, Kern C, Schmiedeknecht G, Bartnik E: Truncation of the amino-terminus of the recombinant aggrecan rAgg1mut leads to reduced cleavage at the aggrecanase site. Efficient aggrecanase catabolism may depend on multiple substrate interactions. Matrix Biol. 2000, 19: 533-543. 10.1016/S0945-053X(00)00113-X.PubMed

57.

Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ: Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem. 2000, 275: 33038-33045. 10.1074/jbc.275.42.33038.PubMed

58.

Rodríguez-Manzaneque JC, Milchanowski AB, Dufour EK, Leduc R, Iruela-Arispe ML: Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem. 2000, 275: 33471-33479. 10.1074/jbc.M002599200.PubMed

59.

Gao G, Westling J, Thompson VP, Howell TD, Gottschall PE, Sandy JD: Activation of the proteolytic activity of ADAMTS4 (aggrecanase-1) by C-terminal truncation. J Biol Chem. 2002, 277: 11034-11041. 10.1074/jbc.M107443200.PubMed

60.

Arner EC, Pratta MA, Trzaskos JM, Decicco CP, Tortorella MD: Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J Biol Chem. 1999, 274: 6594-6601. 10.1074/jbc.274.10.6594.PubMed

61.

Kashiwagi M, Tortorella M, Nagase H, Brew K: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem. 2001, 276: 12501-12504. 10.1074/jbc.C000848200.PubMed

62.

Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada Y: Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett. 2001, 494: 192-195. 10.1016/S0014-5793(01)02323-7.PubMed

63.

Amour A, Slocombe PM, Webster A, Butler M, Knight CG, Smith BJ, Stephens PE, Shelley C, Hutton M, Knäuper V, Docherty AJ, Murphy G: TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett. 1998, 435: 39-44. 10.1016/S0014-5793(98)01031-X.PubMed

64.

Amour A, Knight CG, Webster A, Slocombe PM, Stephens PE, Knäuper V, Docherty AJ, Murphy G: The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett. 2000, 473: 275-279. 10.1016/S0014-5793(00)01528-3.PubMed

65.

Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM: ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun. 2000, 278: 511-515. 10.1006/bbrc.2000.3835.PubMed

66.

Yu WH, Yu S, Meng Q, Brew K, Woessner JF: TIMP-3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem. 2000, 275: 31226-31232. 10.1074/jbc.M000907200.PubMed

67.

Apte SS, Hayashi K, Seldin MF, Mattei MG, Hayashi M, Olsen BR: Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev Dyn. 1994, 200: 177-197.PubMed

68.

Su S, Grover J, Roughley PJ, DiBattista JA, Martel-Pelletier J, Pelletier JP, Zafarullah M: Expression of the tissue inhibitor of metalloproteinases (TIMP) gene family in normal and osteoarthritic joints. Rheumatol Int. 1999, 18: 183-191. 10.1007/s002960050083.PubMed

69.

Su S, DiBattista JA, Sun Y, Li WQ, Zafarullah M: Up-regulation of tissue inhibitor of metalloproteinases-3 gene expression by TGF-beta in articular chondrocytes is mediated by serine/threonine and tyrosine kinases. J Cell Biochem. 1998, 70: 517-527. 10.1002/(SICI)1097-4644(19980915)70:4<517::AID-JCB8>3.3.CO;2-R.PubMed

70.

Li WQ, Zafarullah M: Oncostatin M up-regulates tissue inhibitor of metalloproteinases-3 gene expression in articular chondrocytes via de novo transcription, protein synthesis, and tyrosine kinase- and mitogen-activated protein kinase-dependent mechanisms. J Immunol. 1998, 161: 5000-5007.PubMed

71.

Takizawa M, Ohuchi E, Yamanaka H, Nakamura H, Ikeda E, Ghosh P, Okada Y: Production of tissue inhibitor of metalloproteinases 3 is selectively enhanced by calcium pentosan polysulfate in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2000, 43: 812-820. 10.1002/1529-0131(200004)43:4<812::AID-ANR11>3.0.CO;2-Y.PubMed

72.

Munteanu SE, Ilic MZ, Handley CJ: Calcium pentosan polysulfate inhibits the catabolism of aggrecan in articular cartilage explant cultures. Arthritis Rheum. 2000, 43: 2211-2218. 10.1002/1529-0131(200010)43:10<2211::AID-ANR8>3.0.CO;2-D.PubMed

73.

Munteanu SE, Ilic MZ, Handley CJ: Highly sulfated glycosaminoglycans inhibit aggrecanase degradation of aggrecan by bovine articular cartilage explant cultures. Matrix Biol. 2002, 21: 429-440. 10.1016/S0945-053X(02)00034-3.PubMed

74.

Arner EC, Pratta MA, Decicco CP, Xue CB, Newton RC, Trzaskos JM, Magolda RL, Tortorella MD: Aggrecanase. A target for the design of inhibitors of cartilage degradation. Ann NY Acad Sci. 1999, 878: 92-107.PubMed

75.

Yao W, Wasserman ZR, Chao M, Reddy G, Shi E, Liu RQ, Covington MB, Arner EC, Pratta MA, Tortorella M, Magolda RL, Newton R, Qian M, Ribadeneira MD, Christ D, Wexler RR, Decicco CP: Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors. J Med Chem. 2001, 44: 3347-3350. 10.1021/jm015533c.PubMed

76.

Yao W, Chao M, Wasserman ZR, Liu RQ, Covington MB, Newton R, Christ D, Wexler RR, Decicco CP: Potent P1' biphenylmethyl substituted aggrecanase inhibitors. Bioorg Med Chem Lett. 2002, 12: 101-104. 10.1016/S0960-894X(01)00704-1.PubMed

77.

Cai L, Yin JP, Starovasnik MA, Hogue DA, Hillan KJ, Mort JS, Filvaroff EH: Pathways by which interleukin 17 induces articular cartilage breakdown in vitro and in vivo. Cytokine. 2001, 16: 10-21. 10.1006/cyto.2001.0939.PubMed

78.

Sabatini M, Thomas M, Deschamps C, Lesur C, Rolland G, de Nanteuil G, Bonnet J: Effects of ceramide on aggrecanase activity in rabbit articular cartilage. Biochem Biophys Res Commun. 2001, 283: 1105-1110. 10.1006/bbrc.2001.4920.PubMed

79.

Stanton H, Ung L, Fosang AJ: The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem J. 2002, 364: 181-190.PubMedCentralPubMed

80.

Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T: Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002, 46: 2648-2657. 10.1002/art.10531.PubMed

81.

Curtis CL, Hughes CE, Flannery CR, Little CB, Harwood JL, Caterson B: n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation. J Biol Chem. 2000, 275: 721-724. 10.1074/jbc.275.2.721.PubMed

82.

Tortorella MD, Malfait AM, Deccico C, Arner E: The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage. 2001, 9: 539-552. 10.1053/joca.2001.0427.PubMed

83.

Little CB, Hughes CE, Curtis CL, Jones SA, Caterson B, Flannery CR: Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum. 2002, 46: 124-129. 10.1002/1529-0131(200201)46:1<124::AID-ART10121>3.0.CO;2-X.PubMed

84.

Koshy PJ, Lundy CJ, Rowan AD, Porter S, Edwards DR, Hogan A, Clark IM, Cawston TE: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 2002, 46: 961-967. 10.1002/art.10212.PubMed

85.

Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS: Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol. 2002, 168: 1405-1412.PubMed

86.

Curtis CL, Rees SG, Little CB, Flannery CR, Hughes CE, Wilson C, Dent CM, Otterness IG, Harwood JL, Caterson B: Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum. 2002, 46: 1544-1553. 10.1002/art.10305.PubMed

87.

Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner LA, Hutchinson NI, Singer II, Donatelli SA, Weidner JR, Williams HR, Mumford RA, Lohmander LS: Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest. 1997, 100: 93-106.PubMedCentralPubMed

88.

Fosang AJ, Last K, Maciewicz RA: Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest. 1996, 98: 2292-2299.PubMedCentralPubMed

89.

Little CB, Flannery CR, Hughes CE, Mort JS, Roughley PJ, Dent C, Caterson B: Aggrecanase versus matrix metalloproteinases in the catabolism of the interglobular domain of aggrecan in vitro. Biochem J. 1999, 344: 61-68. 10.1042/0264-6021:3440061.PubMedCentralPubMed

90.

Little CB, Hughes CE, Curtis CL, Janusz MJ, Bohne R, Wang-Weigand S, Taiwo YO, Mitchell PG, Otterness IG, Flannery CR, Caterson B: Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol. 2002, 21: 271-88. 10.1016/S0945-053X(02)00004-5.PubMed

91.

Fosang AJ, Last K, Stanton H, Weeks DB, Campbell IK, Hardingham TE, Hembry RM: Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem. 2000, 275: 33027-33037. 10.1074/jbc.M910207199.PubMed

92.

Stanton H, Fosang AJ: Matrix metalloproteinases are active following guanidine hydrochloride extraction of cartilage: generation of DIPEN neoepitope during dialysis. Matrix Biol. 2002, 21: 425-428. 10.1016/S0945-053X(02)00035-5.PubMed

93.

Sztrolovics R, White RJ, Roughley PJ, Mort JS: The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism. Biochem J. 2002, 362: 465-472. 10.1042/0264-6021:3620465.PubMedCentralPubMed

94.

Lee ER, Lamplugh L, Davoli MA, Beauchemin A, Chan K, Mort JS, Leblond CP: Enzymes active in the areas undergoing cartilage resorption during the development of the secondary ossification center in the tibiae of rats ages 0–21 days: I. Two groups of proteinases cleave the core protein of aggrecan. Dev Dyn. 2001, 222: 52-70. 10.1002/dvdy.1168.PubMed

95.

Maroudas A, Bayliss MT, Uchitel-Kaushansky N, Schneiderman R, Gilav E: Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch Biochem Biophys. 1998, 350: 61-71. 10.1006/abbi.1997.0492.PubMed

96.

Sandy JD, Verscharen C: Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J. 2001, 358: 615-626. 10.1042/0264-6021:3580615.PubMedCentralPubMed

97.

van Meurs JB, van Lent PL, Holthuysen AE, Singer II, Bayne EK, van den Berg WB: Kinetics of aggrecanase- and metalloproteinase-induced neoepitopes in various stages of cartilage destruction in murine arthritis. Arthritis Rheum. 1999, 42: 1128-1139. 10.1002/1529-0131(199906)42:6<1128::AID-ANR9>3.0.CO;2-2.PubMed

98.

van Meurs J, van Lent P, Stoop R, Holthuysen A, Singer I, Bayne E, Mudgett J, Poole R, Billinghurst C, van der Kraan P, Buma P, van den Berg W: Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity. Arthritis Rheum. 1999, 42: 2074-2084. 10.1002/1529-0131(199910)42:10<2074::AID-ANR7>3.0.CO;2-5.PubMed

99.

Mudgett JS, Hutchinson NI, Chartrain NA, Forsyth AJ, McDonnell J, Singer II, Bayne EK, Flanagan J, Kawka D, Shen CF, Stevens K, Chen H, Trumbauer M, Visco DM: Susceptibility of stromelysin 1-deficient mice to collagen-induced arthritis and cartilage destruction. Arthritis Rheum. 1998, 41: 110-121. 10.1002/1529-0131(199801)41:1<110::AID-ART14>3.3.CO;2-7.PubMed

100.

Mort JS, Magny MC, Lee ER: Cathepsin B: an alternative protease for the generation of an aggrecan 'metalloproteinase' cleavage neoepitope. Biochem J. 1998, 335: 491-494.PubMedCentralPubMed

101.

Mason RM, Chambers MG, Flannelly J, Gaffen JD, Dudhia J, Bayliss MT: The STR/ort mouse and its use as a model of osteoarthritis. Osteoarthritis Cartilage. 2001, 9: 85-91. 10.1053/joca.2000.0363.PubMed

102.

Chambers MG, Cox L, Chong L, Suri N, Cover P, Bayliss MT, Mason RM: Matrix metalloproteinases and aggrecanases cleave aggrecan in different zones of normal cartilage but colocalize in the development of osteoarthritic lesions in STR/ort mice. Arthritis Rheum. 2001, 44: 1455-1465. 10.1002/1529-0131(200106)44:6<1455::AID-ART241>3.0.CO;2-J.PubMed

103.

Sasaki M, Seo-Kiryu S, Kato R, Kita S, Kiyama H: A disintegrin and metalloprotease with thrombospondin type1 motifs (ADAMTS-1) and IL-1 receptor type 1 mRNAs are simultaneously induced in nerve injured motor neurons. Brain Res Mol Brain Res. 2001, 89: 158-163. 10.1016/S0169-328X(01)00046-8.PubMed

104.

Singer II, Scott S, Kawka DW, Bayne EK, Weidner JR, Williams HR, Mumford RA, Lark MW, McDonnell J, Christen AJ, Moore VL, Mudgett JS, Visco DM: Aggrecanase and metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of mice with collagen II-induced arthritis. Osteoarthritis Cartilage. 1997, 5: 407-418.PubMed

105.

Lemons ML, Sandy JD, Anderson DK, Howland DR: Intact aggrecan and fragments generated by both aggrecanse and metalloproteinase-like activities are present in the developing and adult rat spinal cord and their relative abundance is altered by injury. J Neurosci. 2001, 21: 4772-4781.PubMed

106.

Satoh K, Suzuki N, Yokota H: ADAMTS-4 (a disintegrin and metalloproteinase with thrombospondin motifs) is transcriptionally induced in beta-amyloid treated rat astrocytes. Neurosci Lett. 2000, 289: 177-180. 10.1016/S0304-3940(00)01285-4.PubMed

107.

Konttinen YT, Mandelin J, Li TF, Salo J, Lassus J, Liljestrom M, Hukkanen M, Takagi M, Virtanen I, Santavirta S: Acidic cysteine endoproteinase cathepsin K in the degeneration of the superficial articular hyaline cartilage in osteoarthritis. Arthritis Rheum. 2002, 46: 953-960. 10.1002/art.10185.PubMed

108.

Lang A, Horler D, Baici A: The relative importance of cysteine peptidases in osteoarthritis. J Rheumatol. 2000, 27: 1970-1979.PubMed

Titel: Aggrecanases and cartilage matrix degradation
verfasst von: Hideaki Nagase
Masahide Kashiwagi
Publikationsdatum: 01.03.2003
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 2/2003
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar630

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Aggrecanases and cartilage matrix degradation

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2003

New hope for haplotype mapping

A need for a 'whole-istic functional genomics' approach in complex human diseases: arthritis

The VH gene repertoire of splenic B cells and somatic hypermutation in systemic lupus erythematosus

Systemic lupus erythematosus and the type I interferon system

The clinical relevance of autoantibodies in scleroderma

CD4+CD25+ immunoregulatory T cells may not be involved in controlling autoimmune arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin